8-K: BridgeBio Oncology Therapeutics to Go Public Through Merger with Helix Acquisition Corp. II

BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II (HLXB) have announced a definitive business combination agreement to create a publicly listed biotechnology company focused on advancing a pipeline of RAS and PI3K-targeting medicines.

Summary

• TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics (BBOT)) and Helix Acquisition Corp. II (Nasdaq: HLXB) have entered into a definitive business combination agreement.
• Upon closing, the combined company will be named BridgeBio Oncology Therapeutics, Inc. and is expected to be listed on Nasdaq under the ticker symbol BBOT.
• The transaction is expected to provide BBOT with approximately $550 million in cash, including $196 million from Helix's trust account (assuming no redemptions) and $260 million from a concurrent PIPE financing.
• The PIPE is led by Cormorant Asset Management and includes other institutional investors.
• The proceeds will be used to accelerate the development of BBOT's three lead programs: BBO-8520, BBO-10203, and BBO-11818.
• The business combination is expected to be completed in the third quarter of 2025, subject to stockholder approvals and other customary closing conditions.
• Assuming a share price of $10.36 per share and no redemptions, BBOT is expected to have an implied pro forma equity value of approximately $949 million at closing.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The merger provides BBOT with significant funding and a public listing, but the company still faces significant clinical and regulatory risks. The management comments and investor interest are encouraging, but the forward-looking statements are qualified by numerous risk factors.

Positives

• The merger provides BBOT with significant capital to advance its clinical programs.
• The PIPE financing demonstrates strong investor confidence in BBOT's pipeline and management team.
• BBOT's pipeline targets significant unmet needs in RAS and PI3K-driven cancers.
• BBOT's management team has a proven track record of developing new medicines.
• BBOT's assets are designed to be synergistic across several indications to achieve the most benefit for broad patient populations.
• BBO-8520 has shown responses across all dose levels of monotherapy escalation while supporting a favorable safety profile.

Negatives

• The transaction is subject to stockholder approvals and other closing conditions, which could delay or prevent the merger from being completed.
• The combined company will be subject to the risks associated with operating as a public company.
• The market price of the combined company's stock may be volatile.
• There is a risk of redemption requests from Helix II's public shareholders, which could reduce the cash available to the combined company.
• BBOT has a limited operating history, has not completed any clinical trials, has no products approved for commercial sale and has not generated any revenue, which may make it difficult for investors to evaluate our current business and likelihood of success and viability.
• BBOT has incurred significant net losses in each period since our inception, and we expect to continue to incur significant net losses for the foreseeable future.

Risks

• Clinical trials may fail to demonstrate the safety and efficacy of BBOT's product candidates.
• Regulatory approvals may be delayed or not obtained.
• BBOT may face substantial competition from other companies developing cancer therapies.
• BBOT's product candidates may not achieve adequate market acceptance.
• BBOT relies on third parties for manufacturing and clinical trials.
• The combined company may experience difficulties in managing its growth.
• The market price of the combined company's common stock may be volatile.
• The consummation of the business combination is subject to a number of conditions, including regulatory approvals, any third party consents, and shareholder approvals, and if those conditions are not satisfied or waived, the business combination may not be completed.
• HLXB public stockholders can redeem some or all of the funds held in trust, and significant redemptions could materially impact our cash position and runway.

Future Outlook

BBOT expects net proceeds from the transaction to provide the capital needed to accelerate the development of three lead programs: BBO-8520, BBO-10203, and BBO-11818, with multiple clinical assets with anticipated value inflection points over the next 9-18 months.

Management Comments

• Eli Wallace, PhD., Chief Executive Officer of BBOT, said 'This financing and transaction mark a significant milestone for our company. We are profoundly grateful to the patients who participate in our trials, our dedicated BBOT team members, and our investors. We believe this transaction is the optimal path to advance our programs and make a meaningful impact on patients affected by deadly cancers.'
• Bihua Chen, Founder and Chief Executive Officer of Cormorant, and Chief Executive Officer of Helix, said 'BBOT's team has some of the brightest minds in oncology, with a proven track record of developing new medicines. The company's pipeline has the potential for paradigm-shifting impact on the treatment of some of the highest prevalence malignancies and we look forward to seeing patient impact further materialize as the clinical trials move forward.'

Industry Context

This announcement reflects the ongoing trend of biotech companies seeking public listings through SPAC mergers, particularly in the oncology space. The focus on RAS and PI3K pathways aligns with the industry's interest in developing targeted therapies for prevalent cancer drivers.

Comparison to Industry Standards

• Several companies are developing KRAS inhibitors, including Mirati Therapeutics (adagrasib) and Amgen (sotorasib). BBOT's BBO-8520 aims to differentiate itself by targeting both the ON and OFF states of KRASG12C.
• PI3K inhibitors are also being developed by companies like Novartis and Roche. BBOT's BBO-10203 aims to improve upon existing PI3K inhibitors by selectively blocking PI3K/AKT signaling in the tumor and decreasing the risk for hyperglycemia/hyperinsulinemia.
• The $949 million pro forma equity value is within the range of other recent biotech SPAC mergers, but the ultimate success will depend on the clinical trial results and commercial potential of BBOT's pipeline.

Stakeholder Impact

• Shareholders of Helix II will have the opportunity to vote on the business combination.
• Patients with RAS and PI3K-driven cancers could benefit from the development of new therapies.
• Employees of BBOT will become part of a publicly listed company.
• The transaction could create value for the stakeholders of both BBOT and Helix II.

Next Steps

• Helix II intends to prepare and file a registration statement on Form S-4 with the SEC.
• Helix II will mail a definitive proxy statement/prospectus to its shareholders.
• Stockholder approvals from both BBOT and Helix are required.
• The business combination is expected to be completed in the third quarter of 2025.
• BBOT expects to dose the first patient with BBO-11818 in the first half of 2025.
• Expansion studies are planned for 2H 2025 for ONKORAS-101.

Key Dates